問卷

TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

篩選

List

3168Cases

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
  • Condition/Disease

    Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Test Drug

    NS-863

Participate Sites
6Sites

Not yet recruiting1Sites

2022-03-01 - 2022-08-04

Phase I/II

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2022-03-01 - 2024-07-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A phase 2, randomized, double-blind, placebo-controlled, dose-exploration trial was conducted to evaluate the efficacy and safety of oral NS-863 in participants with pulmonary arterial hypertension (PAH).
  • Condition/Disease

    Pulmonary hypertension

  • Test Drug

    NS-863

Participate Sites
5Sites

Not yet recruiting1Sites

2022-03-01 - 2026-12-31

Phase IV

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2022-03-25 - 2026-03-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

Terminated1Sites

2022-03-31 - 2024-12-02

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting7Sites

2022-03-31 - 2024-08-30

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2022-03-31 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting4Sites